Your browser doesn't support javascript.
loading
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Tettero, Jesse M; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjorn T; Gradowska, Patrycja; Griskevicius, Laimonas; Janssen, Jeroen J W M; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G; Pabst, Thomas; Passweg, Jakob; Porkka, Kimmo; Valk, Peter J M; Löwenberg, Bob; Ossenkoppele, Gert J; Cloos, Jacqueline.
Afiliação
  • Tettero JM; Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Ngai LL; Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Bachas C; Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Breems DA; Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium.
  • Fischer T; Otto von Guericke University Hospital Magdeburg, Magdeburg, Germany.
  • Gjertsen BT; Haukeland University Hospital, Bergen, Norway.
  • Gradowska P; Dutch-Belgian Hemato-Oncology Cooperative Group Data Center-Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Griskevicius L; Vilnius University Hospital Santaros Klinikos and Vilnius University, Vilnius, Lithuania.
  • Janssen JJWM; Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Juliusson G; Skanes University Hospital, Lund, Sweden.
  • Maertens J; University Hospital Gasthuisberg, Leuven, Belgium.
  • Manz MG; University Hospital, Zurich, Switzerland; Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland.
  • Pabst T; Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland; Department of Medical Oncology, Inselspital; University Hospital, Bern, Switzerland.
  • Passweg J; Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland; University Hospital, Basel, Switzerland.
  • Porkka K; Helsinki University Hospital Cancer Center, Helsinki, Finland.
  • Valk PJM; Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Löwenberg B; Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Ossenkoppele GJ; Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Cloos J; Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands. j.cloos@amsterdamumc.nl.
Haematologica ; 108(10): 2794-2798, 2023 10 01.
Article em En | MEDLINE | ID: mdl-37021540
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article